EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections

Ryan Z Z Lew iD, Douglas J W Tay, Jocelyn W X Ong, Jing Hui Low, Jing Liu, De Yun Wang iD, Justin J H Chu iD, Anand Kumar Andiappan iD, Kai Sen Tan, Vincent T K Chow iD

Cells · 24.06.2026 · 15 (13) · 1146

DOI: 10.3390/cells15131146 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, online erschienen am 24.06.2026. Verfasst von Ryan Z Z Lew und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 117545, Singapore. Hauptthemen laut MEDLINE: Ivermectin, Antiviral Agents, Adenosine Monophosphate, Alanine. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 68 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National University of Singapore, National Medical Research Council (N.M.R.C.) Singapore, National University Health System Seed Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The COVID-19 pandemic highlighted the urgent need to develop effective and broad-spectrum antiviral therapies against coronaviruses. One strategy to address this concern is a combination therapy using repurposed drugs against zoonotic viruses with pandemic potential. We previously demonstrated that the combination of Remdesivir and Ivermectin is highly potent and synergistic in inhibiting the replication of murine hepatitis virus (MHV) in RAW264.7 macrophages. This study investigated the interactions between the drug combination, coronavirus and host by proteomics and RNA sequencing of MHV-infected H2.35 murine liver epithelial cells. Time-of-addition and time-of-removal assays suggested that the drug combination likely affected the synthesis of viral RNA and viral protein. This combination drastically diminished the live virus titer greater than the respective monotherapies in MHV-infected H2.35 cells (by ~4 log10), as well as in SARS-CoV-2-infected VeroE6 cells and human nasal epithelial cells. Proteomic and transcriptomic analyses revealed that viral protein and RNA levels were significantly depressed upon combination treatment. The drug combination exhibited considerable negative effects upon host RNA processes and resulted in the upregulation of host protein processes (e.g., response to unfolded protein; protein insertion into ER membrane). Molecular pathways affected by the combination treatment were markedly distinct from the monotherapies and indicated that Ivermectin enhances Remdesivir by modulating critical host processes to synergistically exert its inhibitory effect on the coronavirus replication cycle.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

IvermectinAntiviral AgentsAdenosine MonophosphateAlanineSARS-CoV-2Murine hepatitis virusCOVID-19 Drug TreatmentCoronavirus InfectionsAnimalsMiceHumansChlorocebus aethiopsVero CellsDrug SynergismVirus ReplicationCell LineProteomicsEpithelial CellsRNA, ViralDrug Therapy, Combination

Stichwörter der Autor:innen

IvermectinRemdesivirSARS-CoV-2combination therapyhost pathwaysmurine hepatitis virusproteomicsrepurposed drugstranscriptomics

Substanzen

IvermectinAntiviral AgentsremdesivirAdenosine MonophosphateAlanineRNA, Viral

Autor:innen und Institutionen

  • Department of Microbiology and Immunology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 117545, Singapore.
  • NUS Medicine Biosafety Level 3 Core Facility, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 117599, Singapore.
  • Infectious Diseases Translational Research Program, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 117597, Singapore.
  • Singapore Immunology Network, Agency for Science, Technology and Research, Biopolis, Singapore 138648, Singapore.
  • Department of Otolaryngology, Yong Loo Lin School of Medicine, National University of Singapore, Kent Ridge, Singapore 119228, Singapore.

ORCID-Profile: Ryan Z Z Lew, De Yun Wang, Justin J H Chu, Anand Kumar Andiappan, Vincent T K Chow

Förderung

  • National University of Singapore
  • National Medical Research Council (N.M.R.C.) Singapore
  • National University Health System Seed Funding
  • NUSMed BSL3 S3RT
  • IAF-PP
  • Singapore Immunology Network A*STAR

Zitieren

APA

Lew, R. Z. Z., Tay, D. J. W., Ong, J. W. X., Low, J. H., Liu, J., Wang, Y., Chu, J. J. H., Andiappan, A. K., Tan, K. S., & Chow, V. T. K. (2026). Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections. Cells, 15(13), 1146. https://doi.org/10.3390/cells15131146

Vancouver

Lew RZZ, Tay DJW, Ong JWX, Low JH, Liu J, Wang Y, et al. Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections. Cells. 2026;15(13):1146. doi:10.3390/cells15131146

BibTeX
@article{Lew2026,
  author = {Lew, Ryan Z Z and Tay, Douglas J W and Ong, Jocelyn W X and Low, Jing Hui and Liu, Jing and Wang, De Yun and Chu, Justin J H and Andiappan, Anand Kumar and Tan, Kai Sen and Chow, Vincent T K},
  title = {Combination of Remdesivir and Ivermectin Exerts Highly Potent and Synergistic Antiviral Activity Against Murine Coronavirus and SARS-CoV-2 Infections},
  journal = {Cells},
  year = {2026},
  volume = {15},
  number = {13},
  pages = {1146},
  doi = {10.3390/cells15131146}
}
Kostenlos starten →